Form 4: Cardiff Oncology CSO Tod Smeal Receives Stock Options

Chief Scientific Officer Tod Smeal was granted 300,000 stock options in Cardiff Oncology, Inc. as part of an equity incentive.

Summary

• Tod Smeal, Chief Scientific Officer of Cardiff Oncology, Inc., was granted 300,000 stock options on April 14, 2026.
• The options have an exercise price of $1.63 per share.
• The options expire on April 14, 2036.
• Vesting schedule: 75,000 options vest on April 14, 2027, with the remaining 225,000 vesting in 36 equal monthly installments thereafter.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that carries no significant change in company strategy or financial outlook.

Positives

• Aligns the interests of the Chief Scientific Officer with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future performance of the company's common stock price relative to the $1.63 exercise price.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a disclosure of an executive equity transaction.

Industry Context

StockSavvy.ai notes that equity grants to key scientific leadership are standard practice in the biotechnology sector to retain talent and incentivize the achievement of clinical development milestones.

Comparison to Industry Standards

• The use of a four-year vesting schedule with a one-year cliff is consistent with standard executive compensation practices in the U.S. biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first tranche of 75,000 options on April 14, 2027.

Key Dates

Keywords

Cardiff Oncology, CRDF, Form 4, Insider Trading, Stock Options, Executive Compensation